Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations

Pathology Research and Practice

Volumn 210, Issue 3, 2014, Pages 176-181

  Jie Liu, ^a   Li, Xing Ya ^b   Zhao, Yan Qiu ^a   Liu, Rui Qing ^c   Zhang, Jian Bo ^a   Ma, Jie ^a   Chen, Li Juan ^a   Hu, Xiu Feng ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Lung cancer; Pulmonary surfactant associated protein; Thyroid transcription factor 1

Indexed keywords

ADENOCARCINOMA; EPIDERMAL GROWTH FACTOR RECEPTOR; LUNG CANCER; PULMONARY SURFACTANT-ASSOCIATED PROTEIN; THYROID TRANSCRIPTION FACTOR-1;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, COMPLEX AND MIXED; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893725813     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.11.013     Document Type: Article

References (32)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA. Cancer J. Clin. 2011, 61:212-236.
2. Devesa S.S., Bray F., Vizcaino A.P., Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer 2005, 117:294-299.
3. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K., Yatabe Y., Powell C.A., Beer D., Riely G., Garg K., Austin J.H., Rusch V.W., Hirsch F.R., Jett J., Yang P.C., Gould M. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc. Am. Thorac. Soc. 2011, 8:381-385.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
5. Kaufmann O., Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000, 36:8-16.
6. Takeuchi T., Tomida S., Yatabe Y., Kosaka T., Osada H., Yanagisawa K., Mitsudomi T., Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J. Clin. Oncol. 2006, 24:1679-1688.
7. Saad R.S., Liu Y.L., Han H., Landreneau R.J., Silverman J.F. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum. Pathol. 2004, 35:3-7.
8. Awaya H., Takeshima Y., Yamasaki M., Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am. J. Clin. Pathol. 2004, 121:644-653.
9. Saad R.S., Cho P., Silverman J.F., Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am. J. Clin. Pathol. 2004, 122:421-427.
10. Phelps D.S., Floros J. Localization of surfactant protein synthesis in human lung by in situ hybridization. Am. Rev. Respir. Dis. 1988, 137:939-942.
11. Auten R.L., Watkins R.H., Shapiro D.L., Horowitz S. Surfactant apoprotein A (SP-A) is synthesized in airway cells. Am. J. Respir. Cell Mol. Biol. 1990, 3:491-496.
12. Wohlford-Lenane C.L., Snyder J.M. Localization of surfactant-associated proteins SP-A and SP-B mRNA in rabbit fetal lung tissue by in situ hybridization. Am. J. Respir. Cell Mol. Biol. 1992, 7:335-343.
13. Newton C.R., Graham A., Heptinstall L.E., Powell S.J., Summers C., Kalsheker N., Smith J.C., Markham A.F. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989, 17:2503-2516.
14. Ninomiya H., Hiramatsu M., Inamura K., Nomura K., Okui M., Miyoshi T., Okumura S., Satoh Y., Nakagawa K., Nishio M., Horai T., Miyata S., Tsuchiya E., Fukayama M., Ishikawa Y. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009, 63:235-240.
15. Inamura K., Ninomiya H., Ishikawa Y., Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. Arch. Pathol. Lab. Med. 2010, 134:66-72.
16. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., Gerald W.L., Travis W.D. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am. J. Surg. Pathol. 2008, 32:810-827.
17. Finberg K.E., Sequist L.V., Joshi V.A., Muzikansky A., Miller J.M., Han M., Beheshti J., Chirieac L.R., Mark E.J., Iafrate A.J. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J. Mol. Diagn. 2007, 9:320-326.
18. Sun P.L., Seol H., Lee H.J., Yoo S.B., Kim H., Xu X., Jheon S., Lee C.T., Lee J.S., Chung J.H. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J. Thorac. Oncol. 2012, 7:323-330.
19. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., Heelan R.T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:1103-1109.
20. West H.L., Franklin W.A., McCoy J., Gumerlock P.H., Vance R., Lau D.H., Chansky K., Crowley J.J., Gandara D.R. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J. Clin. Oncol. 2006, 24:1807-1813.
21. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., Kris M.G., Sandler A.B., Carbone D.P., Tsao A., Herbst R.S., Heller G., Ladanyi M., Pao W., Johnson D.H. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 2008, 26:1472-1478.
22. Kim Y.H., Ishii G., Goto K., Nagai K., Tsuta K., Shiono S., Nitadori J., Kodama T., Nishiwaki Y., Ochiai A. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin. Cancer Res. 2004, 10:7311-7317.
23. Jian Z., Tomizawa Y., Yanagitani N., Iijima H., Sano T., Nakajima T. Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes. Pathol. Int. 2005, 55:619-625.
24. Yatabe Y., Borczuk A.C., Powell C.A. Do all lung adenocarcinomas follow a stepwise progression?. Lung Cancer 2011, 74:7-11.
25. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin. Roentgenol. 2005, 40:90-97.
26. Yoshida Y., Shibata T., Kokubu A., Tsuta K., Matsuno Y., Kanai Y., Asamura H., Tsuchiya R., Hirohashi S. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005, 50:1-8.
27. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Nakayama H., Kameda Y., Tsuchiya E., Miyagi Y. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod. Pathol. 2007, 20:967-973.
28. Sakamoto H., Shimizu J., Horio Y., Ueda R., Takahashi T., Mitsudomi T., Yatabe Y. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J. Pathol. 2007, 212:287-294.
29. Tang X., Kadara H., Behrens C., Liu D.D., Xiao Y., Rice D., Gazdar A.F., Fujimoto J., Moran C., Varella-Garcia M., Lee J.J., Hong W.K., Wistuba I.I. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin. Cancer Res. 2011, 17:2434-2443.
30. Vincenten J., Smit E.F., Vos W., Grunberg K., Postmus P.E., Heideman D.A., Snijders P.J., Meijer G., Kuik J., Witte B.I., Thunnissen E. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. J. Thorac. Oncol. 2012, 7:1522-1527.
31. Zamecnik J., Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002, 440:353-361.
32. Mendelson C.R. Role of transcription factors in fetal lung development and surfactant protein gene expression. Annu. Rev. Physiol. 2000, 62:875-915.